Moderna announces data from Phase 1 mRNA cancer vaccine study
Category: #health  By Nikita Chaurasia  Date: 2019-06-03
  • share
  • Twitter
  • Facebook
  • LinkedIn

Moderna announces data from Phase 1 mRNA cancer vaccine study

The data revealed Moderna’s mRNA personalized cancer vaccine (PCV) mRNA-4157 to be well-tolerated at all tested doses and elicited neoantigen-specific T-cell responses.

Massachusetts-based biotechnology firm, Moderna, Inc. has recently announced interim data from its ongoing Phase 1 clinical study in patients with both unresected (advanced) and resected (adjuvant) solid tumors.

According to reports, the data showed Moderna’s mRNA PCV (personalized cancer vaccine) mRNA-4157, given separately or in conjunction with Merck’s pembrolizumab (KEYTRUDA®), to be well-tolerated at all tested doses and elicited neoantigen-specific T-cell responses. Furthermore, there were no vaccine-related SAEs (serious adverse events) reported for PCV when directed to patients as a monotherapy or in conjunction with pembrolizumab.

Demonstrated at the 2019 American Society of Clinical Oncology (ASCO) Annual Meeting, the study showed Moderna’s mRNA platform’s immunogenicity for creating PCVs. In addition, the clinical activity was observed in some patients receiving mRNA-4157 in combination with pembrolizumab.

Reports cite that these tolerability, safety and immunogenicity data and the observed initial clinical activity support Moderna’s randomized Phase 2 study examining pembrolizumab in combination with a 1 mg dose of mRNA-4157, compared to pembrolizumab alone, for the treatment of high-risk adjuvant melanoma.

Speaking on the trial, Tal Zaks, M.D., Ph.D., CMO, Moderna, said that the company is encouraged by these interim data from its PCV program, which includes designing and manufacturing of a unique vaccine for individual patient depending on their specific tumor. Zaks claims that this study validates Moderna’s mRNA PCV’s ability to elicit T-cells that are specific to the cancer mutations.

Moreover, the company has also observed early signs of clinical activity of its personalized cancer vaccine in combination with pembrolizumab, including in two patients who were prior treated with checkpoint inhibitors.

Adding further Zaks claims that the firm is looking forward to building on these learnings about immunogenicity and tolerability by assessing activity in a randomized Phase 2 study for the treatment of adjuvant melanoma.

Source Credit: https://investors.modernatx.com/news-releases/news-release-details/moderna-announces-presentation-interim-data-phase-1-study-mrna

https://www.biospace.com/article/releases/moderna-announces-presentation-of-interim-data-from-phase-1-study-of-mrna-personalized-cancer-vaccine-at-2019-asco-annual-meeting/

  • share
  • Twitter
  • Facebook
  • LinkedIn


About Author

Nikita Chaurasia    

Nikita Chaurasia

Having always been daft at wordplay, Nikita Chaurasia, post the completion of post-graduation, commenced her journey into the content generation cosmos. Endowed with a professional MBA degree in Advertising and Public Relations, Nikita strives to integrate her creativ...

Read More

More News By Nikita Chaurasia

Syndax Pharmaceuticals reveals data from phase 1 trial of axatilimab
Syndax Pharmaceuticals reveals data from phase 1 trial of axatilimab
By Nikita Chaurasia

According to reliable sources, Massachusetts-headquartered clinical stage biopharmaceutical company, Syndax Pharmaceuticals Inc. has revealed an updated data from its Phase 1 trial of its patent axatilimab. The company will reportedly present the dat...

Xiaomi shares drop by 7.1% after raising USD 3.9 billion in equity deal
Xiaomi shares drop by 7.1% after raising USD 3.9 billion in equity deal
By Nikita Chaurasia

Shares of Xiaomi Corporation, a Chinese multinational electronics company, witnessed a 7.1% drop during Hong Kong trading after the company secured USD 3.91 billion in fund raising which also included the city’s top-up placement. The company h...

Supercom signs a supply contract of PureSecurity EM suite in Wisconsin
Supercom signs a supply contract of PureSecurity EM suite in Wisconsin
By Nikita Chaurasia

Israel-based leading provider of advanced solutions for cybersecurity, IoT (Internet of Things) and e-Government sectors Supercom has reportedly signed a supply agreement to deliver its PureSecurity EM (Electronic Monitoring) product suite in Wiscons...